CD19 (clone EBS-CD-015), anti-human

Source:
A BALB/c mouse was immunized with NALM1 + NALM16 cells.
Fusion partner: Sp2/0

.

Specifications:
CD19 is a transmembrane glycoprotein that contains two extracellular immunoglobulin-like domains. CD19 is present in both benign and malignant B-cells and is considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centres, in mantle zone cells, and in scattered cells of the inter-follicular areas. Anti-CD19 exhibits an overall immunoreactivity pattern similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, expression of CD19 is continuous throughout B-cell development and through terminal differentiation of B-cells into plasma cells. Anti-CD19 positivity is seen in the vast majority of B-cell neoplasms commonly at a lower intensity than normal B-cell counterparts. Plasma cell neoplasms are nearly always negative, as are T-cell neoplasms.Species reactivityPositive:human.ApplicationsIndicate B cell differentiation in normal and malignant cells. Typing of leukemias and lymphomas. Flow cytometryImmunofluorescenceFrozen sectionsParaffin sections+++―FormatProduced in tissue culture, contains no host Ig. Antibodies are affinity purified and presented in PBS with 0,02% sodium azide.Stored at 4°C-8°C, shelf life is at least 24 months after purchase.Dilution adviceFlow Cytometry (0,5-2,0 μg/million cells in 0,1ml for 30 min, at 4°C). Immunofluorescence (0,5-2,0 μg/ml).Immunohistology (1-2 μg/ml for 30 min at RT; no suitable antigen retrieval procedure is known to date for formalin-fixed tissues).

Species reactivity:
Positive: human.

Applications:
Indicate B cell differentiation in normal and malignant cells. Typing of leukemias and lymphomas.
Flow cytometry: +
Immunofluorescence: +
Frozen sections: +
Paraffin section: ―

Positive control: Human lymph nodes and tonsils.

References:
- Tedder, T.F. and Isaacs, C.M. J. Immunol.143: 712-710 (1889).
- Bejcek BE, et al, Cancer Res.55(11): 2346-51 (1995).